Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701885 | 1.00 | CNR2 (0.50) | CNR2HSD11B1GBA1ATMPIK3CD | |
| SCHEMBL13285011 | 0.86 | CNR2 (0.49) | CNR2HSD11B1GBA1PIK3CDGRM2 | |
| SCHEMBL9891988 | 0.79 | CNR2 (0.54) | CNR2HSD11B1GBA1CNR1 | |
| SCHEMBL3427328 | 0.77 | GBA1 (0.47) | CNR2HSD11B1GBA1GRM2CNR1 | |
| SCHEMBL3427330 | 0.77 | GBA1 (0.47) | CNR2HSD11B1GBA1GRM2CNR1 | |
| SCHEMBL2568082 | 0.76 | CNR2 (0.42) | CNR2HSD11B1GBA1GRM2CNR1 | |
| SCHEMBL16480434 | 0.76 | GBA1 (0.43) | CNR2HSD11B1GBA1PIK3CDCNR1 | |
| SCHEMBL13284755 | 0.76 | GBA1 (0.43) | CNR2HSD11B1GBA1PIK3CDCNR1 | |
| SCHEMBL9891989 | 0.76 | CNR2 (0.51) | CNR2HSD11B1CNR1KDM4E | |
| SCHEMBL9892002 | 0.76 | CNR2 (0.51) | CNR2HSD11B1CNR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010077836-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885HSD11B1 3537/4885GBA1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.